Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: A 12-month open randomized pilot study

Rheumatology

Volumn 46, Issue 6, 2007, Pages 994-998

  Saviola, G ^a   Abdi Ali, L ^a   Shams, Eddin S ^a   Coppini, A ^b   Cavalieri, F ^c   Campostrini, L ^d   Sacco, S ^d   Bucci, M ^d   Cirino, G ^d   Rossini, M ^a  

^a IRCCS   (Italy)

^b Rehabilitation Centre of Bozzolo ^*

^c Castel Goffredo   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Deflazacort; Glucocorticoid induced osteoporosis; Methylprednisolone; Osteoprotegerin; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CALCIUM PHOSPHATE; COLECALCIFEROL; CORTICOTROPIN; CREATININE; CYCLOSPORIN; DEFLAZACORT; DEOXYPYRIDINOLINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESTRADIOL; HYDROXYCHLOROQUINE; LUTEINIZING HORMONE; METHOTREXATE; METHYLPREDNISOLONE; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; SEX HORMONE BINDING GLOBULIN; STEROID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BIOEQUIVALENCE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; HUMAN; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; OPEN STUDY; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OSTEOPOROSIS; PILOT PROJECTS; PREGNENEDIONES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447344038     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem030     Document Type: Article

References (57)

1. Lo Cascio V, Bonucci E, Imbimbo B et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int 1984;36:435-8.
2. Mazziotti G, Angeli A, Bilezikian JP et al. Glucocorticoid induced osteoporosis: An update. Trends Endocrinol Metab 2006;17:144-9.
3. Sinigaglia L, Nervetti A, Male Q et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000;27:2541-2.
4. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: Affect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
5. Saito A Davis JW, Wasnich RD et al. Users of low dose glucocorticoids have increased bone loss rates: A longitudinal study. Calcif Tissue Int 1995;57:115-9.
6. Gough AK, Lilley J, Eyre S et al. Generalized bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
7. Frediani B, Allegri A, Falsetti P et al. Bone mineral density in patients with psoriatic arthritis. J Rheumatol 2001;28:138-43.
8. Oelzner P, Franke S, Muller A et al. Relationship between soluble markers of immune activation and bone turnover in postmenopausal women with rheumatoid arthritis. Rheumatology 1999;38:841-7.
9. Kong YY, Feige U, Sarosi L et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-9.
10. Cortet B, Flipo RM, Blanckaert F et al. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucooorticoid therapy. Rev Rheum 1997;64:451-8.
11. Cortet B, Flipo RM, Pigny P et al. Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 1998;25:2339-44.
12. Cooper C, Coupland C, Mitchel M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
13. Peel NF, Moore DJ, Barrington NA et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid disease. Ann Rheum Dis 1995;54:801-6.
14. Patschan D, Lodderkemper K, Buttgareit F. Molecular mechanism of glucocorticoidinduced osteoporosis. Bone 2001;29:498-505.
15. Canalis E, Bilezikian JP, Angeli A et al. Perspectives on glucocorticoid induced osteoporosiss. Bone 2006;34:593-8.
16. Sivagurunathan S, Muir MM, Brennan TC et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 2005;20:390-8.
17. Sasaki N, Kusano E, Ando Y et al. Glucocorticoid decreases circulating osteoprotegerin: Possible mechanism for glucocorticoid induced osteoporosiss. Nephrol Dial Transplant 2001;16:479-82.
18. Ton FN, Gunawardene SC, Lee H et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005;20:464-70.
19. van StaaTP. Glucocorticoid induced osteoporosis in man. Osteoporos Int 2005; 16:S11.
20. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner Res 2004;19:893-9.
21. Kanis JA, Johnell O, Oden A et al. Intervention thresholds for osteoporosis. Bone 2002;31:26-31.
22. Seeman E. The structural basis of bone fragility in men. Bone 1999;25:143-7.
23. Olszinski WP, Shawn Davison K, Adachi JD et al. Osteoporosis in men: Epidemiology, diagnosis, prevention and treatment. Clin Ther 2004;26:15-28.
24. Seeman E, Estrogen, androgen and the pathogenesis of bone fragility in women and man. Curr Osteoporos Rep 2004;2:90-6.
25. Anderson FH, Francis RM, Selby PL et al. Sex hormones and osteoporosis in men. Calcif Tissue Int 1998;62:185-8.
26. Oh KW, Rhee EJ, Lee WY et al. Circulating osteoprotegerin and receptor activator of NF-kappa B ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol 2005;62:92-8.
27. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004;4:268-75.
28. Szulc P, Hofbauer LC, Heufelder AE et al. Osteoprotegerin serum levels in men: Correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 2001;86;3162-5.
29. Gannari L, Marletti D, Martini G et al. Longitudinal association between sex hormone levels, bone loss and bone turnover in elderly men. J Clin Endocrinol Metab 2003;88:5327-33.
30. Lormeau C, Soudan B, d'Herbomez M et al. Sex hormone-binding globulin, estradiol and bone turnover markers in male osteoporosis. Bone 2004;34:933-9.
31. Falcini T, Trapani S, Ermini M et al. Deflazacort in pediatric rheumatic diseases needs a frequent follow-up bone densitometry. Pediatrics 1995;95:318.
32. Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985;37:592-3.
33. Gray RE, Doherty SM, Galloway J et al. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991;34:287-95.
34. Lippuner K, Casez JP, Horber FF et al. Effects of deflazacort versus prednisone on bone mass, body composition and lipid profile: A randomized, double-blind study in kidney transplant patients. J Clin Endocrinol Metab 1998;83:3795-802.
35. Lo Cascio V, Bonucci P, Dilani S et al. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients; prednisone versus deflazacort. Calcif Tissue Int 1998;62:199-204.
36. Loftus J, Allen A, Hasp R et al. Randomized double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: A relatively bone-sparing effect of deflazacort. Br J Rheumatol 1993;32:31-8.
37. Olggard K, Storm T, v Wowam H et al. Glucocorticoid induced osteoporosis in the lumbar spine, forearm and mandible of nephrotic patients: A double blind study on the high dose, long term effects of prednisone versus deflazacort. Calcif Tissue Int 1992;50:490-7.
38. Russell JE, Gannari C, Imbimbo B, Avioli LV. Effects of deflazacort and the L 6485 metabolite on epiphyseal cartilage carbohydrate metabolism: comparison with prednisone. Horm Metabol Res 1985;17:402-5.
39. Eberhardt R, Kruger K, Reiter W et al. Long-term therapy with the new glucocorticoid deflazacort in rheumatoid arthritis. Drug Res 1994;5:642-7.
40. Broyer M, Terzi F, Lahnert A et al. A controlled study of deflazacort in the treatment of idiopathic nephritic syndrome. Pediatr Naphrol 1997;11:418-22.
41. Avioli LV. Potency ratio - a brief synopsis. Br J Rheumatol 1993;32:24-6.
42. Kroggsgaard MR, Thamsborg G, Lund B. Changes in bone mass during low-dose corticoid treatment in patients with polymyalgia reumatica: A double blind, prospective comparison between prednisoone and deflazacort. Ann Rheum Dis 1996;55:143-6.
43. Lo Cascio V. Deflazacort and bone mass. Clin Exp Rheumatol 2000;18:S69-73.
44. Montecucco M, Caporali R, Caprotti P et al. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. J Rheumatol 1992;19:1895-900.
45. David J, Loftus J, Hasp R et al. Spinal and somatic growth in patients with juvenile chronic arthritis treated for up to 3 years with deflazacort. Clin Exp Rheumatol 1992;10:621-4.
46. Rizzato G, Riboldi A, Imbimbo B et al. The long-term efficacy and safety of two different corticosteroids in chronic saroidosis. Respir Med 1997;91:449-60.
47. Messina OD, Barreira JC, Zanchetta JR et al. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol 1992;19:1520-6.
48. Di Munno O, Imbimbo, B, Mazzantini M et al. Deflazacort versus methylprednisolone in polymyalgia reumatica: Clinical equivalence and relative antinflammatory potency of different treatment regimens. J Rheumatol 1995;22:1492-8.
49. Cacoub P, Chemial K, Khalifa P et al. Deflazacort versus prednisone in patients with giant call arteritis: Effects on bone mass loss. J Rheumatol 2001;28:2474-9.
50. Harris DH. Prednisolone in early rheumatoid arthritis: An antiinvasive affect. Arthritis Rheum 2005;52:3324-5.
51. Svensson B, Boonen A, Albensson C et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. Arthritis Rheum 2005;52:3360-79.
52. Da Silva JA, Jacobs JW, Kirwan JR et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. A rewiew on safety: Published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
53. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988;3:113-5.
54. Kirwan JR, Hickey SH, Hallgren R et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomised controlled trial in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:1415-21.
55. Von Tirpitz C, Epp S, Klaus J et al. Effect of systemic glucocorticoid therapy on bone metabolism and osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Epatol 2003;16:1165-70.
56. Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 2006;38:652-61.
57. Del Rosso A, Cinelli M, Guiducci S et al. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes. Rheumatology 2005;44:1255-62.